ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors; Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program
- Strategic focus of immuno-oncology (I-O) portfolio on modulation of tumor microenvironment to enhance T cell influx and activity in immune...
CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD